Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota3American Board of Anesthesiology, Raleigh, North Carolina.
JAMA. 2013 Dec 4;310(21):2289-96. doi: 10.1001/jama.2013.281954.
Substance use disorder (SUD) among anesthesiologists and other physicians poses serious risks to both physicians and patients. Formulation of policy and individual treatment plans is hampered by lack of data regarding the epidemiology and outcomes of physician SUD.
To describe the incidence and outcomes of SUD among anesthesiology residents.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of physicians who began training in United States anesthesiology residency programs from July 1, 1975, to July 1, 2009, including 44,612 residents contributing 177,848 resident-years to analysis. Follow-up for incidence and relapse was to the end of training and December 31, 2010, respectively.
Cases of SUD (including initial SUD episode and any relapse, vital status and cause of death, and professional consequences of SUD) ascertained through training records of the American Board of Anesthesiology, including information from the Disciplinary Action Notification Service of the Federation of State Medical Boards and cause of death information from the National Death Index.
Of the residents, 384 had evidence of SUD during training, with an overall incidence of 2.16 (95% CI, 1.95-2.39) per 1000 resident-years (2.68 [95% CI, 2.41-2.98] men and 0.65 [95% CI, 0.44-0.93] women per 1000 resident-years). During the study period, an initial rate increase was followed by a period of lower rates in 1996-2002, but the highest incidence has occurred since 2003 (2.87 [95% CI, 2.42-3.39] per 1000 resident-years). The most common substance category was intravenous opioids, followed by alcohol, marijuana or cocaine, anesthetics/hypnotics, and oral opioids. Twenty-eight individuals (7.3%; 95% CI, 4.9%-10.4%) died during the training period; all deaths were related to SUD. The Kaplan-Meier estimate of the cumulative proportion of survivors experiencing at least 1 relapse by 30 years after the initial episode (based on a median follow-up of 8.9 years [interquartile range, 5.0-18.8 years]) was 43% (95% CI, 34%-51%). Rates of relapse and death did not depend on the category of substance used. Relapse rates did not change over the study period.
Among anesthesiology residents entering primary training from 1975 to 2009, 0.86% had evidence of SUD during training. Risk of relapse over the follow-up period was high, indicating persistence of risk after training.
麻醉师和其他医生的物质使用障碍(SUD)对医生和患者都构成严重风险。由于缺乏关于医师 SUD 的流行病学和结果的数据,政策制定和个体治疗计划受到阻碍。
描述麻醉住院医师 SUD 的发生率和结果。
设计、设置和参与者:这是一项对 1975 年 7 月 1 日至 2009 年 7 月 1 日期间在美国麻醉学住院医师培训计划中开始培训的医生进行的回顾性队列研究,共有 44612 名住院医师参与,共提供了 177848 名住院医师年的数据进行分析。发病率和复发的随访时间分别为培训结束和 2010 年 12 月 31 日。
通过美国麻醉委员会的培训记录确定 SUD(包括初始 SUD 发作和任何复发、生存状态和死因以及 SUD 的职业后果)的病例,包括来自联邦州医学委员会纪律行动通知服务的信息和来自国家死亡指数的死因信息。
在住院医师中,有 384 人在培训期间有 SUD 的证据,总体发病率为每 1000 名住院医师年 2.16(95%CI,1.95-2.39)(2.68 [95%CI,2.41-2.98] 男性和 0.65 [95%CI,0.44-0.93] 女性每 1000 名住院医师年)。在研究期间,初始率增加后,1996-2002 年期间的发病率较低,但自 2003 年以来发病率最高(每 1000 名住院医师年 2.87 [95%CI,2.42-3.39])。最常见的物质类别是静脉内阿片类药物,其次是酒精、大麻或可卡因、麻醉剂/催眠药和口服阿片类药物。在培训期间,有 28 人(7.3%;95%CI,4.9%-10.4%)死亡;所有死亡均与 SUD 有关。基于初始发作后 30 年至少经历 1 次复发的幸存者的累积比例的 Kaplan-Meier 估计值(基于中位数随访 8.9 年[四分位距,5.0-18.8 年])为 43%(95%CI,34%-51%)。复发率和死亡率与使用的物质类别无关。复发率在研究期间没有变化。
在 1975 年至 2009 年期间进入初级培训的麻醉住院医师中,有 0.86%的人在培训期间有 SUD 的证据。随访期间的复发风险很高,表明培训后仍存在风险。